CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC

NCT07449065 · clinicaltrials.gov ↗

COMPLETED

Status

324

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Transarterial Chemoembolization
Microvascular Invasion (MVI)
Tyrosine Kinase Inhibitors

Interventions

DRUG: TKI
PROCEDURE: TACE

Sponsor

First Affiliated Hospital, Sun Yat-Sen University